Association of Long-Term Dynamics in Circulating Testosterone with Serum PSA in Prostate Cancer-Free Men with Initial-PSA < 4 ng/mL
We previously reported that an accelerated decline in circulating testosterone level is associated with a higher risk of prostate cancer (PCa). This study is to examine whether testosterone change rate is related to serum prostate-specific antigen (PSA) concentration among PCa-free men. Longitudinal data were derived from electronic medical records at a tertiary hospital in the Southeastern USA. PCa-free men with initial-PSA < 4 ng/mL and ≥ 2 testosterone measurements were included (n = 632). Three PSA measures (peak, the most recent, and average PSA) during the study period (from first testosterone measurement to the most recent hospital visit) were examined using multivariable-adjusted geometric means and were compared across quintiles of testosterone change rate (ng/dL/month) and current testosterone level (cross-sectional). Mean (standard deviation, SD) age at baseline was 59.3 (10.5) years; mean study period was 93.0 (55.3) months. After adjusting for covariates including baseline testosterone, the three PSA measures all significantly increased across quintile of testosterone change rate from increase to decline (peak PSA: quint 1 = 1.09, quint 5 = 1.41; the most recent PSA: quint 1 = 0.85, quint 5 = 1.00; average PSA: quint 1 = 0.89, quint 5 = 1.02; all Ptrend < 0.001). But current testosterone level was not associated with PSA levels. Stratified analyses indicated men with higher adiposity (body mass index > 24.1 kg/m2) or lower baseline testosterone (≤ 296 ng/dL) were more sensitive to testosterone change in regard to PSA. Among PCa-free men, accelerated testosterone decline might correlate with higher serum PSA concentration. It will help to elucidate the mechanisms relating aging-accompanying testosterone dynamics to prostate carcinogenesis.
KeywordsTestosterone Dynamics Aging Prostate-specific antigen (PSA) Prostate cancer
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Isaacs JT. Testosterone and the prostate. Testosterone: action, deficiency, substitution 2004;3:347–74Google Scholar
- 2.Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89(5):2085–2098CrossRefGoogle Scholar
- 10.Xu X, Chen X, Hu H, Dailey AB, Taylor BD (2015) Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model. BMC Cancer 15(806):015–1833Google Scholar
- 15.Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y et al (2014) Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 14(33):1471–2490Google Scholar
- 23.Zhou Y, Bolton EC, Jones JO (2015) Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 54(1):14–0203Google Scholar
- 24.Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M (2018) BMI trajectories and risk of overall and grade-specific prostate cancer: an observational cohort study among men seen for prostatic conditions. Cancer Med 7(10):5272–5280. https://doi.org/10.1002/cam4.1747 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Wang LG, Liu XM, Kreis W, Budman DR (1997) Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 57(4):714–719PubMedGoogle Scholar